First-line ICIs in renal cell carcinoma

• Главные авторы: Vincenzo Fiorentino (Автор), Pietro Tralongo (Автор), Luigi Maria Larocca (Автор), Cristina Pizzimenti (Автор), Maurizio Martini (Автор), Francesco Pierconti (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2023-08-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Treatment of metastatic renal cell carcinoma (mRCC) has radically changed, switching from interferon alfa (IFN-α) and high-dose interleukin−2 (HD IL−2) to new targeted therapies directed against tumoral neoangiogenesis, the mammalian target of the rapamycin (mTOR) pathway and immune checkpoints. Of...